title: Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation.
abstract: BACKGROUND
  Steroid-free immunosuppressive regimens are becoming more common in pancreas transplantation, with persistent concerns regarding its safety and efficacy.
  
  
  METHODS
  We performed a retrospective chart review of 87 pancreas transplant recipients-22 simultaneous pancreas-kidney transplants, 48 pancreas-after-kidney transplants, and 17 pancreas transplant alone-who underwent transplantation within the period of January 2000 to November 2006 and who received induction therapy with thymoglobulin followed by maintenance immunosuppression with tacrolimus and mycophenolate mofetil. We compared one group on a steroid-free regimen (n = 25) with another on a steroid-based regimen (n = 62).
  
  
  RESULTS
  At 6 months, there was no kidney graft loss and no significant difference between groups (steroid-free vs steroid-based groups) in patient survival (100% vs 96.8%), pancreas graft survival (96.0% vs 93.5%), acute rejection (4.0% vs 11.3%), hospitalization for any cause (60.0% vs 51.6%), infection requiring hospitalization (16.0% vs 32.3%), or incidence of BK viremia (0% vs 3.2%). CMV viremia occurred less in the steroid-free group (0% vs 17.7% in the steroid-based group, P = .024). The estimated glomerular filtration rate (eGFR) at 6 months was higher in the steroid-free group (74.8 vs 55.7 mL/min/1.73 m2 in the steroid-based group, P = .001), with fewer occurrences of a 25% decline in eGFR (33.3% among the steroid-free group vs 61.7% among steroid-based group, P = .019), despite similar average tacrolimus exposure (11.7 +/- 3.7 vs 12.2 +/- 2.7 ng/dL, P = .478).
  
  
  CONCLUSIONS
  A steroid-free regimen with thymoglobulin induction followed by tacrolimus and mycophenolate mofetil for maintenance in pancreas transplantation was safe and effective in preventing rejection, with reduced incidence of CMV infection and better-preserved kidney function.
authors.affiliation: Department of Nephrology, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: R
authors.initials: R
authors.lastname: Tanchanco
authors.forename: V
authors.initials: V
authors.lastname: Krishnamurthi
authors.forename: C
authors.initials: C
authors.lastname: Winans
authors.forename: A
authors.initials: A
authors.lastname: Wee
authors.forename: A
authors.initials: A
authors.lastname: Duclos
authors.forename: S
authors.initials: S
authors.lastname: Nurko
authors.forename: R
authors.initials: R
authors.lastname: Fatica
authors.forename: M
authors.initials: M
authors.lastname: Lard
authors.forename: E D
authors.initials: ED
authors.lastname: Poggio
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D005938:Glucocorticoids; D009173:Mycophenolic Acid; D008775:Methylprednisolone